Long‐Term Deep Brain Stimulation in Treatment‐Resistant Obsessive‐Compulsive Disorder: Outcome and Quality of Life at Four to Eight Years Follow‐Up
Author(s) -
Winter Lotta,
Saryyeva Assel,
Schwabe Kerstin,
Heissler Hans E.,
Runge Joachim,
Alam Mesbah,
Heitland Ivo,
Kahl Kai G.,
Krauss Joachim K.
Publication year - 2021
Publication title -
neuromodulation: technology at the neural interface
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.296
H-Index - 60
eISSN - 1525-1403
pISSN - 1094-7159
DOI - 10.1111/ner.13232
Subject(s) - deep brain stimulation , medicine , quality of life (healthcare) , internal capsule , adverse effect , observational study , magnetic resonance imaging , disease , parkinson's disease , radiology , nursing , white matter
Background Obsessive compulsive disorder (OCD) is a severe disabling disease, and around 10% of patients are considered to be treatment‐resistant (tr) in spite of guideline‐based therapy. Deep brain stimulation (DBS) has been proposed as a promising treatment for patients with trOCD. However, the optimal site for stimulation is still a matter of debate, and clinical long‐term follow‐up observations including data on quality of life are sparse. We here present six trOCD patients who underwent DBS with electrodes placed in the bed nucleus of the stria terminalis/anterior limb of the internal capsule (BNST/ALIC), followed for four to eight years after lead implantation. Materials and Methods In this prospective observational study, six patients (four men, two women) aged 32–51 years and suffering from severe to extreme trOCD underwent DBS of the BNST/ALIC. Symptom severity was assessed using the Yale‐Brown Obsessive Compulsive Scale (Y‐BOCS), and quality of life using the World Health Organization Quality of Life assessment scale (WHO‐QoL BREF). Follow‐up was obtained at least for four years in all patients. Results With chronic DBS for four to eight years, four of the six patients had sustained improvement. Two patients remitted and two patients responded (defined as >35% symptom reduction), while the other two patients were considered nonresponders on long‐term. Quality of life markedly improved in remitters and responders. We did not observe peri‐interventional side effects or adverse effects of chronic stimulation. Conclusions Chronic DBS of ALIC provides long‐term benefit up to four to eight years in trOCD, although not all patients take profit. Targeting the BNST was not particularly relevant since no patient appeared to benefit from direct stimulation of the BNST. Quality of life improved in DBS responders, documented by improved QoL scores and, even more important, by regaining of autonomy and improving psychosocial functioning.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom